Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 24, 2022

SELL
$36.77 - $90.91 $129,173 - $319,366
-3,513 Closed
0 $0
Q3 2021

Oct 21, 2021

BUY
$41.79 - $135.3 $35,020 - $113,381
838 Added 31.33%
3,513 $218,000
Q2 2021

Jul 29, 2021

BUY
$32.15 - $89.72 $86,001 - $240,001
2,675 New
2,675 $229,000
Q4 2020

Jan 22, 2021

SELL
$6.79 - $12.25 $106,942 - $192,937
-15,750 Closed
0 $0
Q3 2020

Oct 14, 2020

BUY
$2.86 - $11.51 $45,045 - $181,282
15,750 New
15,750 $183,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $101M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Avantax Advisory Services, Inc. Portfolio

Follow Avantax Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Advisory Services, Inc. with notifications on news.